Carisma Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss

The total revenue of CARM for the last quarter is 3.38 M USD, and it's 63.19% lower compared to the previous quarter. The net income of Q3 24 is -12.70 M USD.